Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of cancer-associated thrombosis by machine learning: results from the Vienna Cancer and Thrombosis Study.

ESMO open·2026
Same author

It's time to improve antithrombotic therapy! A global perspective for antithrombotic stewardship.

European journal of internal medicine·2026
Same author

Absolute quantitative proteomics identifies patterns of plasma proteins associated with venous thromboembolism in patients with colorectal cancer.

Thrombosis research·2026
Same author

The Vienna CATScore for predicting cancer-associated venous thromboembolism: an external validation across multiple time points.

ESMO open·2025
Same author

Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Hamostaseologie·2019
Same journal

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026
Same journal

Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
See all related articles

Related Experiment Video

Updated: Jun 26, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

[Update thrombophilia].

E Lindhoff-Last1, B Luxembourg, I Pabinger

  • 1Med. Klinik III, Schwerpunkt Angiologie/Hämostaseologie, Klinikum der J. W. Goethe- Universität Frankfurt am Main. Lindhoff-Last@em.uni-frankfurt.de

Hamostaseologie
|January 10, 2009
PubMed
Summary
This summary is machine-generated.

Selective thrombophilia screening is cost-effective for identifying venous thromboembolism risks. Screening benefits antiphospholipid syndrome patients and selected pregnant individuals, but generally doesn't alter anticoagulation duration for most venous thrombosis cases.

Related Experiment Videos

Last Updated: Jun 26, 2026

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
08:50

Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis

Published on: January 9, 2026

Area of Science:

  • Hematology
  • Genetics
  • Obstetrics

Context:

  • Thrombophilias, inherited or acquired conditions predisposing to blood clots, present diagnostic and therapeutic challenges.
  • Evidence-based data is crucial for managing thrombophilia and its associated risks.
  • Understanding the epidemiology and clinical manifestations of thrombophilias is essential for effective patient care.

Purpose:

  • To provide a comprehensive survey of thrombophilia definitions, epidemiology, and clinical features.
  • To present evidence-based diagnostic and therapeutic strategies for thrombophilias.
  • To evaluate the cost-effectiveness and clinical utility of thrombophilia screening.

Summary:

  • Selective thrombophilia screening, guided by personal or family history of venous thromboembolism, is more cost-effective than universal screening.
  • Thrombophilia screening results typically do not influence the duration of oral anticoagulation for most venous thrombosis patients.
  • Screening is beneficial for newly diagnosed antiphospholipid syndrome patients and selected pregnant individuals with a history of venous thrombosis.

Impact:

  • Identifies specific patient groups, such as those with antiphospholipid syndrome, who benefit from prolonged anticoagulation.
  • Informs decisions regarding anticoagulation during pregnancy and the puerperium for high-risk individuals.
  • Highlights the need for further research, particularly placebo-controlled trials, to determine the efficacy of anticoagulation in managing pregnancy complications associated with thrombophilia.